- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AZD-4635 | AZD4635
Compound class: Synthetic organic
Comment: Imaradenant (AZD4635) is an orally bioavailable adenosine A2A receptor (A2AR) antagonist . It was developed as a potential immuno-oncology (immunotherapy) drug. Imaradenant reduces the immunosuppressive effects of adenosine within the tumour microenvironment, an activity that rescues immune cell function and it enhances the efficacy of checkpoint inhibitors in syngeneic mouse tumour models .
In 2021 AstraZeneca decided to stop a number of their midphase studies of imaradenant in patients with prostate cancer.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|The A2AR is recognised as a immune checkpoint with immunosuppressive function, and the adenosine/A2AR pathway is expoited by some cancers to suppress antitumour immunity. Antagonism of receptor activation aims to restore the anticancer functions of the immune cell subsets that are sensitive to adenosine.|